These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26996635)

  • 1. Use of non-irradiated blood components in Campath (alemtuzumab)-treated renal transplant patients.
    Hui YM; Regan F; Willecombe M; Taube D
    Transfus Med; 2016 Apr; 26(2):138-46. PubMed ID: 26996635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased bacterial infections after transfusion of leukoreduced non-irradiated blood products in recipients of allogeneic stem cell transplants after reduced-intensity conditioning.
    Jaime-Pérez JC; Villarreal-Villarreal CD; Salazar-Riojas R; Méndez-Ramírez N; Vázquez-Garza E; Gómez-Almaguer D
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):526-30. PubMed ID: 25498924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 66 patients definitive with transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood.
    Uchida S; Tadokoro K; Takahashi M; Yahagi H; Satake M; Juji T
    Transfus Med; 2013 Dec; 23(6):416-22. PubMed ID: 24274074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Missed irradiation of cellular blood components for vulnerable patients: Insights from 10 years of SHOT data.
    Elliot J; Narayan S; Poles D; Tuckley V; Bolton-Maggs PHB
    Transfusion; 2021 Feb; 61(2):385-392. PubMed ID: 33219533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up.
    Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusion-associated graft-versus-host disease with transfusion practice in cardiac surgery.
    Yasuura K; Okamoto H; Matsuura A
    J Cardiovasc Surg (Torino); 2000 Jun; 41(3):377-80. PubMed ID: 10952326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
    Norlin AC; Remberger M
    Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G; Waldmann H
    Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
    Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
    Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretransplant conditioning with Campath-1H (alemtuzumab) in pediatric matched unrelated hematopoietic stem cell transplants: an institutional experience.
    Nageswara Rao AA; Kumar R; Altaf S; Gourde JA; Rodriguez V; Khan SP
    J Pediatr Hematol Oncol; 2012 Mar; 34(2):96-100. PubMed ID: 22146532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
    Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
    Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
    Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline development for prevention of transfusion-associated graft-versus-host disease: reduction of indications for irradiated blood components after prestorage leukodepletion of blood components.
    Wiersum-Osselton JC; Slomp J; Frederik Falkenburg JH; Geltink T; van Duijnhoven HLP; Netelenbos T; Schipperus MR
    Br J Haematol; 2021 Dec; 195(5):681-688. PubMed ID: 34490619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Transfusion-associated graft-versus-host disease].
    Bojanić I; Cepulić BG
    Lijec Vjesn; 2004; 126(1-2):39-47. PubMed ID: 15526751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease.
    Williamson LM; Stainsby D; Jones H; Love E; Chapman CE; Navarrete C; Lucas G; Beatty C; Casbard A; Cohen H
    Transfusion; 2007 Aug; 47(8):1455-67. PubMed ID: 17655590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
    Novitzky N; Thomas V; Hale G; Waldmann H
    Cytotherapy; 2004; 6(2):172-81. PubMed ID: 15203994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors.
    Hamblin M; Marsh JC; Lawler M; McCann SR; Wickham N; Dunlop L; Ball S; Davies EG; Hale G; Waldmann H; Gordon-Smith EC
    Bone Marrow Transplant; 1996 May; 17(5):819-24. PubMed ID: 8733704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
    Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.